AU698356B2 - Disinfection and cleaning of contact lenses - Google Patents
Disinfection and cleaning of contact lensesInfo
- Publication number
- AU698356B2 AU698356B2 AU70836/96A AU7083696A AU698356B2 AU 698356 B2 AU698356 B2 AU 698356B2 AU 70836/96 A AU70836/96 A AU 70836/96A AU 7083696 A AU7083696 A AU 7083696A AU 698356 B2 AU698356 B2 AU 698356B2
- Authority
- AU
- Australia
- Prior art keywords
- protease
- tablet
- contact lenses
- disinfecting solution
- hydrogen peroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000004140 cleaning Methods 0.000 title claims description 74
- 238000004659 sterilization and disinfection Methods 0.000 title claims description 49
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 122
- 230000000249 desinfective effect Effects 0.000 claims description 99
- 239000004365 Protease Substances 0.000 claims description 76
- 102000016938 Catalase Human genes 0.000 claims description 75
- 108010053835 Catalase Proteins 0.000 claims description 75
- 102000035195 Peptidases Human genes 0.000 claims description 74
- 108091005804 Peptidases Proteins 0.000 claims description 74
- 235000019419 proteases Nutrition 0.000 claims description 68
- 229940105657 catalase Drugs 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 36
- 230000000813 microbial effect Effects 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 238000006386 neutralization reaction Methods 0.000 claims description 15
- 108010056079 Subtilisins Proteins 0.000 claims description 13
- 102000005158 Subtilisins Human genes 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 13
- 239000003002 pH adjusting agent Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 229940088598 enzyme Drugs 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 8
- -1 alkali metal salts Chemical class 0.000 claims description 8
- 241000228245 Aspergillus niger Species 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 238000010915 one-step procedure Methods 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 102000012479 Serine Proteases Human genes 0.000 claims description 5
- 108010022999 Serine Proteases Proteins 0.000 claims description 5
- 108090000787 Subtilisin Proteins 0.000 claims description 5
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 5
- 239000002689 soil Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 108091005502 Aspartic proteases Proteins 0.000 claims description 4
- 102000035101 Aspartic proteases Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- 230000004888 barrier function Effects 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 3
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 108090001072 Gastricsin Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 108090000313 Pepsin B Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 235000010338 boric acid Nutrition 0.000 claims description 2
- 125000005619 boric acid group Chemical class 0.000 claims description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 150000004679 hydroxides Chemical class 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 108010009355 microbial metalloproteinases Proteins 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 229940066716 pepsin a Drugs 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 235000011182 sodium carbonates Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 235000011008 sodium phosphates Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 241000228257 Aspergillus sp. Species 0.000 claims 1
- 102000003908 Cathepsin D Human genes 0.000 claims 1
- 108090000258 Cathepsin D Proteins 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 1
- 101100005318 Mus musculus Ctsr gene Proteins 0.000 claims 1
- 102100039652 Pepsin A-5 Human genes 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- OWMBTIRJFMGPAC-UHFFFAOYSA-N dimethylamino 2-methylprop-2-enoate Chemical compound CN(C)OC(=O)C(C)=C OWMBTIRJFMGPAC-UHFFFAOYSA-N 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 239000000243 solution Substances 0.000 description 71
- 229960002163 hydrogen peroxide Drugs 0.000 description 50
- 241000283690 Bos taurus Species 0.000 description 10
- 101710116791 Catalase R Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 239000000645 desinfectant Substances 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000011942 Slow Virus disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000055441 Gastricsin Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000286904 Leptothecata Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- UBGOFPKOVIKDPL-UHFFFAOYSA-M sodium;hydroxy-[4-[(2-hydroxyacetyl)amino]phenyl]arsinate Chemical compound [Na+].OCC(=O)NC1=CC=C([As](O)([O-])=O)C=C1 UBGOFPKOVIKDPL-UHFFFAOYSA-M 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 108010031354 thermitase Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
- A61L12/124—Hydrogen peroxide; Peroxy compounds
- A61L12/126—Hydrogen peroxide; Peroxy compounds neutralised with catalase or peroxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
- A61L12/124—Hydrogen peroxide; Peroxy compounds
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Eyeglasses (AREA)
- Detergent Compositions (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Description
Title: Disinfection and cleaning of contact lenses
FIELD OF THE INVENTION
The present invention relates to a one-step method for disin¬ fecting and cleaning contact lenses of the type using hydrogen peroxide as the disinfecting agent, a protease as the cleaning agent and a catalase for neutralizing the hydrogen peroxide in the aqueous disinfecting solution.
Further, the invention relates to a tablet or capsule suitable for one-step disinfection and cleaning, a one-step disinfection and cleaning system and further a one-step procedure for disin- fection and cleaning contact lenses.
BACKGROUND OF THE INVENTION
Quite a lot of people today prefer wearing contact lenses to glasses. Some people use contact lenses for aesthetic reasons, as they believe that glasses make them look awkward. Other people value the freedom of movement that contact lenses give, which is advantageous when e .g. playing a game of soccer or attending a high-impact aerobics class. Then again some people just do not like the inconvenience of polishing greasy glasses.
Even though contact lenses have been improved during the last decades and posses many advantages in comparison to glasses, contact lenses still need to be disinfected and cleaned period¬ ically, in most cases every day, to avoid infections and discomfort for the wearer.
The development of products for disinfection and cleaning of contact lenses have made the "daily task" easier. However, most contact lens users still regard the disinfection and cleaning task as a troublesome task.
Whether the contact lenses are hard or soft, opticians usually recommend to disinfect the lenses daily and clean them weekly.
Disinfection prevent growth of bacteria on the surface of the contact lenses which might lead to infection of the eyes and making it impossible to wear contact lenses for days.
Cleaning is normally performed by an enzyme capable of degrad- ing debris and/or soil build up on the contact lenses surface. These deposits reduce the wearing comfort as only a reduced amount of oxygen is capable of penetrating the contact lenses to the eyes, and as the friction between the eyes and the contact lenses is increased.
After a cleaning and/or disinfection procedure the contact lenses need to be rinsed thoroughly to remove all enzymatic activity and/or disinfecting agent, e .g. by using a physi¬ ological saline solution.
In the case of the disinfecting agent being hydrogen peroxide a number of catalases have been known to be used as neutralizing agents.
Catalases E.C. 1.11.1.6 (Enzyme Nomenclature, Academic Press, Inc, 1992) are enzymes which catalyze the conversion of hydro¬ gen peroxide (H2O2) to water (H2O) and oxygen (02) .
A plethora of methods for disinfection and cleaning of contact lenses are known. Proteases are often used for cleaning contact lenses as described in US patent no. 3,910,296 (Allergan) .
CA 1,146,881 (Bedding) concerns a method for cleaning contact lenses using enzymes, where the cleaning procedure is followed by rinsing of the lenses, e .g. with saline, to remove active enzymes from the lens.
US patent no. 4,670,178 (Allergan) discloses a method for simultaneous cleaning and disinfection of contact lenses with a protease in hydrogen peroxide. The cleaning is effected by presence of protease activity and shown to be very efficient. After the cleaning and disinfection procedure the activity of the disinfecting and cleaning agent need to be removed from the lenses before use.
EP patent application no. 147,100 (Ciba Geigy) concerns clean¬ ing and disinfection of contact lenses with a hydrogen peroxide solution in the presence of a solid sustained release composi¬ tion which slowly releases a peroxide inactivator. The lenses may be treated with a wetting or comfort solution before inserting into the eyes. However, cleaning and disinfection with hydrogen peroxide does not remove proteinaceous deposits effectively from the surface of the contact lenses.
WO 86/07264 (Kellway Pharm. Ltd.) describes a method for disinfection and cleaning of contact lenses with hydrogen peroxide using a catalase immobilized in a container for neutralization of the hydrogen peroxide. This way excess hydrogen peroxide is decomposed without washing and rinsing.
WO 93/17721 (Genencor Int. Inc.) describes an improved method for cleaning and disinfection of contact lenses comprising disinfection with hydrogen peroxide and decomposition of the residual hydrogen peroxide in the solution with catalase enzyme (CatR) derived from the filamentous fungus Aspergillus niger.
WO 95/02044 (Novo Nordisk A/S) concerns two acidic proteases active in the presence of hydrogen peroxide in concentrations up to as high as 5 wt.%. Example 5 of said application de¬ scribes cleaning and disinfection of contact lenses using one of said acidic proteases as the cleaning agent and hydrogen peroxide as the disinfecting agent. Further, it is mentioned that catalase may be used for neutralization of the hydrogen
peroxide .
Cleaning and disinfection of contact lenses is regarded as a troublesome daily task by most contact lens wearer. Further, prior art methods for disinfection and cleaning of contact lenses are not very safe and consumer convenient as the risk of e.g. forgetting a step is very much present, as at least two not continuous steps need to be carried out.
Therefore, there is a need for more safe and consumer conveni¬ ent disinfection and cleaning methods and systems. A one-step disinfecting and cleaning systems for contact lenses would in¬ crease the safety and consumer convenience.
SUMMARY OF THE INVENTION
The object of the present invention is to facilitate the daily troublesome task of disinfecting and cleaning contact lenses and to make the task more safe to perform.
In the first aspect the invention relates to a one-step method for disinfection and cleaning of contact lenses comprising the steps: a) disinfection of the contact lenses in an aqueous disin- fecting solution comprising from 1 wt.% to 5 wt.% hydrogen peroxide at a pH not acceptable to the eyes, b) cleaning the contact lenses by subjecting the contact lenses to a protease being inactivated within a period of time at a pH level not acceptable to the eyes, c) neutralization of the hydrogen peroxide in the aqueous disinfecting solution with a microbial catalase being substan¬ tially active at pH 3.0 to 7.0, d) adjusting the pH in the aqueous disinfecting solution to a pH level acceptable to the eyes.
The invention also relates to a tablet or capsule for disin¬ fection and cleaning of contact lenses, wherein the tablet is a
multi-layer tablet, comprising i) a protease being irreversibly inactivated within a period of time in an aqueous disinfecting solution at a pH level not ac¬ ceptable to the eyes, and ii) a microbial catalase being substantially active at pH 3.0 to 7.0, iii) an agent capable of adjusting the disinfecting solution to a pH acceptable to the eyes.
The invention is also directed toward a one-step system for disinfection and cleaning of contact lenses comprising a) an aqueous disinfecting solution comprising 1 wt.% to 5 wt.% hydrogen peroxide, and b) a tablet or capsule comprising i) a protease being irreversibly inactivated within a period of time in the aqueous disinfecting solution at a pH level not acceptable to the eyes, and ii) a microbial catalase being substantially active at pH 3.0 to 7.0, iϋ) an agent capable of adjusting the aqueous disinfecting solution to a pH acceptable to the eyes.
Finally the invention relates to a one-step procedure for disinfection and cleaning of contact lenses, comprising the steps of
1) soaking the contact lenses in a fixed amount of an aqueous disinfecting solution comprising 1 wt.% to 5 wt.% hydrogen per¬ oxide, and
2) adding a tablet of the invention, and 3) storing the contact lenses in the aqueous disinfecting solu¬ tion for a period of time.
DETAILED DESCRIPTION OF THE INVENTION
The object of the present invention is to facilitate the daily troublesome task of disinfecting and cleaning contact lenses and to make the task more safe to perform.
In the context of the present invention disinfection and cleaning of contact lenses is of the type involving the steps: a) disinfection of the contact lenses in an aqueous solution comprising between 1 wt.% and 5 wt.% hydrogen peroxide, espe¬ cially 3 wt.% hydrogen peroxide, and b) cleaning the contact lenses with a protease to remove debris and/or soil, and c) neutralization of the hydrogen peroxide in the aqueous disinfecting solution with a catalase.
The present inventors have solved some of the problems of prior art disinfecting and cleaning systems by providing a more safe consumer convenient system.
A more safe and consumer convenient disinfecting and cleaning system means that the system, in comparison to corresponding prior art systems using the same above mentioned principles, have at least one of the following the following advantages: - reduces or eliminates the risk of using the system incorrectly (i.e. the system is more safe to use) ; facilitates the disinfection and cleaning task for the contact lens user (i.e. more easy to use); - reduces the amount of steps to be performed by the contact lens user (i.e. less work to be done and less time are needed to perform the disinfection and cleaning task) .
The present invention can be used for disinfection and cleaning of all types of contact lenses including hard, soft, rigid gas permeable lenses and silicone lenses etc..
The basic principle of the present invention is to use a suit¬ able protease which is inactivated in the aqueous disinfecting solution during cleaning, due to e . g . pH influence, temperature influence or the like. Before being completely inactivated the protease must have had sufficient time and sufficient enzyme activity to clean the contact lenses.
It is to be understood that it is within the scope of the invention to use the disinfection and cleaning principle of the invention for corresponding disinfecting and cleaning proce- dures including separate disinfecting and cleaning (i.e. two- step methods) .
In the first aspect the invention relates to a one-step method for disinfection and cleaning of contact lenses comprising the steps: a) disinfection of the contact lenses in an aqueous disinfec¬ ting solution comprising from 1 wt.% to 5 wt.% hydrogen per¬ oxide at a pH not acceptable to the eyes, b) cleaning the contact lenses by subjecting the contact lenses to a protease being inactivated within a period of time at a pH level not acceptable to the eyes, c) neutralization of the hydrogen peroxide in the aqueous dis¬ infecting solution with a microbial catalase being substanti¬ ally active at pH 3.0 to 7.0, d) adjusting the pH in the aqueous disinfecting solution to a pH level acceptable to the eyes.
A pH level not acceptable to the eyes means in the context of the present invention a pH within the ranges from about pH 8.0 to 13.0 and within the range about pH 1.0 to 6.0. A pH level acceptable to the eyes means a pH within the range from between about pH 6.0 to 8.0.
The above method of the invention may be performed in any of the following step sequences: i) a)-b)-c)-d) , or ii) a)-c)-b)-d), or iii) a)-b)-d)-c), or iv) a)-b)/c)-d), wherein step b) and step c) are performed simultaneously.
In a preferred embodiment of the method of the invention the aqueous disinfecting solution is a conventional commercial disinfecting solution comprising about 3 wt.% hydrogen peroxide at pH 3.5 (e.g. Oxysept®l from Allegan) .
At least in the context of the present invention "one-step" disinfection and cleaning means that the contact lens user's task consists of one continuous step only, which can be per¬ formed within few seconds and without any additional steps before the contact lenses are ready to wear.
The combined daily disinfection and cleaning makes the recom¬ mended weekly cleaning superfluous, as the amount of build-up debris and/or soil on the contact lenses' surfaces are dimin- ished considerably. The daily disinfection and cleaning results in improved wearing comfort.
According to the invention all the present protease activity must be irreversibly inactivated within a fixed period of time to be defined.
If, for instance, the protease in question is to be irreversib¬ ly inactivated within a very short period of time the amount of protease must be relatively large to ensure cleaning of the contact lenses before complete inactivation of the protease. If, in contrast hereto, the protease in question is to be inactivated very slowly over a longer period of time only a very little amount of protease is needed.
The inactivation period for the protease may be from about 1 to 10 minutes to about 1, 2, 3 and no more than 4 hours.
A reduced amount of protease is needed when cleaning daily in comparison to cleaning weekly. The optimal amount of active protease to be added to the aqueous disinfecting solution to effectively clean the contact lenses before all protease activity has been inactivated by pH inactivation can easily be
determined by a person skilled in the art.
Contemplated amounts of protease lies in the range from 0.5 μg to 50 μg preferably 1 μg to 25 μg, especially 2 μg to 10 μg enzyme protein/ml.
The protease used according to the invention may be any neu¬ tral, acidic or alkaline protease being irreversibly inac¬ tivated within a period of time (see above) in a disinfecting solution at a pH not acceptable to the eyes.
For instance, if the protease is an alkaline (or neutral) protease the pH of the aqueous disinfecting solution should be acidic in order to irreversible inactivate the protease.
Suitable proteases can be εelected from the group comprising serine proteases, aspartic proteases, cysteine proteases and metallo proteases.
Also contemplated as suitable is truncated, modified or vari¬ ants proteases of the above listed groups.
Examples of preferred serine proteases are trypεins, chymo- trypsins and alkalophilic subtilisins.
Most preferred are the Bacillus derived alkaline serine pro¬ teases, such as subtilisin A, subtilisin BPN', subtilisin Carlsberg, subtilisin PB92, subtilisin 309, subtilisin 147, subtilisin 168, subtilisin DY, aqualysin or thermitase, trun- cations, modification and variants thereof.
Examples of cysteine proteases include papain and bro elain.
To the group of suitable metallo proteases are e . g . Neutrase® and collagenase.
Examples of aspartic proteases are e .g. pepsin A, pepsin B, pepsin C, chymosin, cathepsin B and renin.
Bovine liver catalases have normally been chosen for neutral- ization of hydrogen peroxide solutions for disinfection of con¬ tact lenses. However, due to fear that a slow-virus disease (Bovine Spongiform Encephalopathy (BSE) ) , which have been iden¬ tified in European cattle herds, might spread to man, a need to find an alternative to bovine liver catalase have been sought.
The risk of spreading the slow-virus disease to man can be avoided by using microbial catalases,, such as catalases deri¬ vable from bacteria, filamentous fungi or yeasts.
The stability of microbial catalases, such as e . g. the micro¬ bial catalases mentioned below, are better at acidic pHs in comparison to "standard" bovine liver catalase. Consequently it is advantageous to use microbial catalases for neutralization of hydrogen peroxide in disinfecting solutions for contact lenses with an acidic pH.
A few such suitable microbial catalases have been suggested for contact lens purposes. Catalases derived from the filamentous fungus Aspergillus niger have even been shown to posses prop- erties which makes them superior to bovine liver catalases.
Aspergillus niger produces two catalases designated Catalase-A (CatA) and Catalase-R (CatR) . CatR is four time as effective than "standard" bovine liver catalase in application requiring neutralization of a concentrated hydrogen peroxide solution. In other words CatR neutralizes hydrogen peroxide in conventional disinfecting solution (i.e. 3 wt.% H2θ , pH 3.5) much faster than standard bovine liver catalase. Further, CatR is more stable than bovine liver catalase toward proteolysis, extreme pH, temperature, hydrogen peroxide and inactivation by glu¬ taraldehyde, SDS, etc. (see WO 93/17721 from Genencor) .
Furthermore, CatR is substantially active at pH in the presence of 3 wt.% hydrogen peroxide from at least pH 3.0 and 7.0, while the activity of conventional bovine liver catalase decreases drastically from pH 7.0 toward pH 3.0.
According to the present invention it has been found that a microbial catalase being substantially active at pH 3.0 to 7.0, preferably at pH 3.0 to 4.5, may advantageously be used for neutralization of hydrogen peroxide in aqueous disinfecting solutions for contact lenses together with a protease being irreversibly inactivated within a period of time in the disin¬ fecting solution at a pH not acceptable to the eyes. Example 1 shows that Subtilisin A is a such suitable protease.
"A catalase being substantially active" at pH 3.0 to 7.0, preferably 3.0 to 4.5, defines a catalase having a relative enzymatic activity within said pH-ranges (pH-optimum defines 100%) higher than 60%, better 70%, even better more than 80%, such as 90%, and in the best case up to about 100%.
The combination of a protease being inactivated within a period of time at a pH level not acceptable to the eyes and a microbi¬ al catalase for disinfection and cleaning of contact lenses results in a very fast one-step process and a system being very safe and consumer convenient.
Further, said combination secure that the one-step method of the invention results in a fast and efficient disinfection of the contact lenses, as the protease removes the soil matrix in which the bacteria (to be killed by the hydrogen peroxide) are present. Consequently, due to this the accessibility for the hydrogen peroxide to the bacteria is very good. As the microbi¬ al catalase is active within a broad pH range the neutraliz- ation can occur immediately reducing the period of time needed for performing the total disinfecting and cleaning task.
The microbial catalase may advantageously be any of the cata¬ lases mentioned above, such as an Aspergillus niger catalase, in particular CatR.
The microbial catalase may also be the Aspergillus niger catalase disclosed by Novo Nordisk A/S in 1990 for neutraliza¬ tion of hydrogen peroxide in aqueous disinfecting solutions for contact lenses.
At present it is believed that the best mode of the present invention is obtained by combining the serine protease subti¬ lisin A (available from Novo Nordisk as Cleanlens®Pro) , as the protease, and the A. niger catalase named CatR described in WO 93/17721, as the microbial. In this specific embodiment the protease will be irreversibly inactivated at a pH level in the range between 1.0 to 4.5 within a suitable period of time.
The agent capable of adjusting the pH in the aqueous disinfect- ing solution may be any suitable agent acceptable to the eyes. For instance the pH adjusting agent may be a buffer, an acid or a base.
The purpose of the pH adjustment is to secure that the contact lenses safely can be entered directly from the aqueous disin¬ fecting solution into the eyes, without any risk of damaging the eyes.
A suitable buffer may be selected from the group of buffers including alkali metal salts, such as potassium or sodium carbonates, acetates, borates, sodium or potassium phosphates, citrates, and hydroxides, and weak acids such as acetic and boric acids.
In the second aspect the invention relates to a tablet, capsule or the like which uses the principles of the method of the invention.
Even though it is believed that the optimal way to introduce the protease, catalase, and pH adjusting agent into the aqueous disinfecting solution is in the form of a tablet or the like, it is to be understood that also other embodiments have been contemplated by the inventors and should be regarded as encom¬ passed by the scope of the present invention. For instance, the protease, catalase and pH adjusting agent may be added to the aqueous disinfecting solution as liquids or a combination of liquids and solids.
A multi layer tablet constructed for one-step disinfection and cleaning of contact lenses comprises i) a protease being irreversibly inactivated within a period of time in an aqueous disinfecting solution at a pH not acceptable to the eyes, and ii) a microbial catalase being substantially active at pH 3.0 to 7.0, iii) an agent capable of adjusting the aqueous disinfecting solution to a pH acceptable to the eyes.
The definition of "..a pH level not acceptable to the eyes", and "....a pH level acceptable to the eyes" is described above.
The tablet may have any suitable embodiment. Four suitable embodiments will be described as examples below. The action of the four embodiments of the tablet (i.e. A, B, C and D) , when used for one-step disinfection and cleaning, will also be described below.
In the first embodiment the multi-layer tablet A comprises a) an outer layer or coating comprising said microbial catalase being substantially active at pH 3.0 to 7.0, and b) a layer within said outer layer comprising a protease being irreversibly inactivated within a period of time in an aqueous disinfecting solution at a pH level not acceptable to the eyes, and
c) an agent capable of adjusting the disinfecting solution to a pH acceptable to the eyes.
In the second embodiment the multi layer tablet B comprises a) an outer layer or coating comprising a protease being irreversibly inactivated within a period of time in an aqueous disinfecting solution at a pH level not acceptable to the eyes, and b) a layer within said outer layer comprising said microbial catalase being substantially active at pH 3.0 to 7.0, and c) an agent capable of adjusting the disinfecting solution to a pH acceptable to the eyes.
In a third embodiment the multi layer tablet C comprises a) an outer layer or coating comprising a protease being irreversibly inactivated within a period of time in an aqueous disinfecting solution at a pH not acceptable to the eyes, b) a layer within said outer layer comprising an agent capable of adjusting the disinfecting solution to a pH acceptable to the eyes, and c) a core comprising a microbial catalase being substantially active at pH 3.0 to 7.0.
In the forth embodiment the multi layer tablet D comprises a) an outer layer or coating comprising a protease being irreversibly inactivated within a period of time in an aqueous disinfecting solution at a pH not acceptable to the eyes and a microbial catalase being substantially active at pH 3.0 to 7.0, and b) a core comprising an agent capable of adjusting the aqueous disinfecting solution to a pH acceptable to the eyes.
The protease and microbial catalase may be any of the above mention proteases and catalases.
The broad pH activity level of the microbial catalase is advantageous as adjustment to a precise pH in an aqueous
disinfecting solution becomes less crucial, which again render the strict and timely control of the release of the catalase layer in the tablet less important.
Said pH adjusting agent may be any suitable agent, such as a buffer or an acid or a base which is capable of adjusting the pH in the aqueous disinfecting solution to a level acceptable to the eyes.
The core and layers of the multi tablet may be separated by a barrier or a membrane. Said barrier may in an embodiment of the invention be made of a water soluble polymer layer, preferably a water soluble film.
Examples of said water soluble film comprises polymers soluble in an acidic medium, such as polymers of dimethylamino ethacry- late and neutral methacrylate esters.
Alternatively the film comprises a pH neutral soluble polymer. Suitable polymers are e .g. soluble cellulose ethers, such as methylcellulose, methylhydroxycellulose , methylhydroxyethyl¬ cellulose, hydroxypropylcellulose, hydroxypropyimethylcellu¬ lose, hydroxyethylcellulose, sodium carboxymethylcellulose, cellulose acetate phthalate, hydroxypropyimethylcellulose phthalate, a polymer of methacrylic acid and methacrylate esters, a copolymer of methacrylic acid and methacrylate esters, a copolymer of methyl vinyl ether and maleic acid anhydride and polyvinyl alcohols.
In still another embodiment the tablet comprises a sparingly soluble core and one or two outer layers having the active constituents dispersed or distributed.
Suitable plasticizers of polyhydric alcohols and water may be added to the above listed soluble film polymers to control the diffusion rate. Preferred plasticizers for this purpose are 1,2-propylene glycol, polyethylene glycols and citrate esters.
In a preferred embodiment the tablet is a controlled release tablet of the type where the content in the outer layer is first released followed by content in the second layer after a period of time, and finalized by the release of the core content after a period of time. One of or both layers or the core content may be released slowly.
The release time of the pH adjusting agent should be so long that the protease has sufficient time to degrade composites on the contact lenses' surface.
As the catalase is substantially active within a broad pH range the neutralization ability of the catalase is not dependent on the action of the pH adjusting agent.
In a further embodiment of the invention the content in the second layer and/or core content is(are) released delayed to the aqueous disinfecting solution.
Additional components may be added to or incorporated into the tablet or capsule which do not substantially decrease the activity of the active components.
Examples are components such as effervescing agents, stabi¬ lizers, chelating agent and/or sequestering agents, colouring agent, tonicity adjusting agents, surfactant and the like. In addition binders, lubricants, carriers, and other excipients normally used in producing tablets may be incorporated.
Effervescing agents are typically employed when the enzymes are provided in solid form. Examples of suitable effervescing agent include, tartaric or citric acid used in combination with suitable alkali metal salts, such as sodium carbonate.
As the tablet of the invention is to be used in an aqueous disinfecting solution it may contain one or more of suitable
chelating agents and/or sequestering agent, tonicity adjusting agent and surfactant.
Suitable tonicity adjusting agents include sodium and potassium chloride, dextrose, calcium and magnesium chloride.
Suitable surfactants can either be cationic, anionic, nonionic or amphoteric. Preferred surfactants are neutral or nonionic.
Specific examples include polyethylene glycol ethers of fatty acids, polyoxypropylene ethers of C12-C18 alkanes and polyxye- thylene, polyoxypropylene block copolymers of ethylene diamine (i.e. poloxamine) .
Examples of preferred chelating agents include Ethylenediami¬ netetraacetic acid (EDTA) and its salts (disodium) and certain polyvinyl alcohols.
The tablet of the invention constitutes together with an aqueous disinfecting solution comprising 1 wt.% to 5 wt.% hydrogen peroxide a one-step disinfecting and cleaning system for contact lenses.
An ideal consumer convenient disinfection and cleaning pro- cedure is carried out in only one continuous step, e.g. in connection with storing the contact lenses for the night, resulting in that the contact lenses are ready for wearing directly from the storage container the next morning without any additional work.
According to the invention the contact lens user only need to introduce the contact lenses into a fix amount of an aqueous disinfecting solution comprising hydrogen peroxide and add a tablet the invention. Said tablet perform the cleaning and disinfection task and further neutralizes the hydrogen peroxide in a safe manner.
Consequently, the one-step system of the invention reduces the work to be done for the contact lens user when performing the disinfecting and cleaning task; facilitates the disinfecting and cleaning task, as only one continuous step need to be performed; eliminates the risk of using the system incorrectly, (e .g. forgetting to neutralize the contact lenses after disin¬ fection and/or cleaning before wear) , as the procedure can be performed continuously within few seconds.
The one-step system of the invention comprises a) an aqueous disinfecting solution comprising 1 wt.% to 5 wt.% hydrogen peroxide, and b) a tablet or capsule comprising i) a protease being irreversibly inactivated within a period of time in an aqueous aqueous disinfecting solution at a pH not acceptable to the eyes, and ii) a microbial catalase being substantially active at pH 3.0 to 7.0 for neutralizing the hydrogen peroxide, and iii) an agent capable of adjusting the pH in the aqueous disinfecting solution to a pH level acceptable to the eyes.
In a preferred embodiment of the invention hydrogen peroxide is present in the aqueous disinfecting solution in 3 wt.% (pH 3.5) .
The tablet or capsule of the invention may advantageously be used as a constituent in the one-step system of the invention.
In the following one-step disinfecting and cleaning of contact lenses using tablet A, B, C and D is roughly described.
One-step disinfection and cleaning using tablet A The contact lenses are immersed in a conventional 3 wt.% hydrogen peroxide disinfecting solution (pH 3.5) together with multi layer tablet A. Initially the hydrogen peroxide disin-
fects the contact lenses. The microbial catalase (comprised in the outer layer) is released leading to neutralization of the hydrogen peroxide in the aqueous disinfecting solution. After a period of time the protease (comprised in the layer below the outer layer) is released into the disinfecting solution and the contact lenses are cleaned. Within a period of time the prote¬ ase is irreversibly inactivated. Finally the buffer (comprised in the core of the tablet) is released resulting in that the pH increases to a pH acceptable to the eyes. The contact lenses are ready to wear directly from the aqueous disinfecting solution.
One-step disinfection and cleaning using tablet B The contact lenses are immersed in a conventional 3 wt.% hydro- gen peroxide disinfecting solution (pH 3.5) together with multi layer tablet B. Initially the hydrogen peroxide disinfects the contact lenses. The protease (comprised in the outer layer) is released into the disinfecting solution and cleans the contact lenses. Within a period of time the protease is irreversibly inactivated. After a period of time the microbial catalase
(comprised in the layer below the outer layer) is released re¬ sulting in neutralization of the hydrogen peroxide in the disinfecting solution. Finally the buffer (comprised in the core of the tablet) is released increasing the pH to a level acceptable to the eyes. The lenses are ready to wear directly from the aqueous disinfecting solution.
One-step disinfection and cleaning using tablet C The contact lenses are immersed in a conventional 3 wt.% hydro- gen peroxide disinfecting solution (pH 3.5) together with multi layer tablet C. Initially the hydrogen peroxide disinfects the contact lenses. The protease (comprised in the outer layer) is released into the disinfecting solution and cleans the contact lenses. Within a period of time the protease is irreversibly inactivated. After a period of time the buffer (comprised in the layer below the outer layer) is released resulting in that the pH is increased to a level acceptable to the eyes. The
catalase (comprised in the core of the tablet) is released resulting in neutralization of the hydrogen peroxide in the aqueous disinfecting solution. The lenses are ready to wear directly from the aqueous disinfecting solution.
One-step disinfection and cleaning using tablet D The contact lenses are immersed in a conventional 3 wt.% hydrogen peroxide disinfecting solution (pH 3.5) together with multi layer tablet D. Initially the hydrogen peroxide disin- fects the contact lenses. The protease and the microbial catalase (comprised in the outer layer) are released into the disinfecting solution. The contact lenses are cleaned by the protease and the hydrogen peroxide is neutralized by the catalase. Within a period of time the protease is irreversibly inactivated. After a period of time the buffer (comprised in the core of the tablet) is released resulting in that the pH is increased to a level acceptable to the eyes. The lenses are ready to wear directly from the aqueous disinfecting solution.
The above examples of one-step disinfection and cleaning proves the advantageous use of the combination of a protease and a microbial catalase.
As the microbial catalase (in contrast to bovine liver cata- lase) is active at pH 3.5 the catalase can neutralize the hydrogen peroxide at the same time as the protease cleans the contact lenses.
Finally the invention relates to a one-step procedure for disinfecting and cleaning contact lenses, comprising the steps of
1) soaking the contact lenses in a fixed amount of an aqueous disinfecting solution comprising 1 wt.% to 5 wt% hydrogen peroxide, preferably 3 wt%, and 2) adding a tablet according to the invention,
3) storing the contact lenses in the aqueous disinfecting solution for a period of time.
The aqueous disinfecting solution must constitute a fixed amount which will normally be between 1 ml and 10 ml, especial¬ ly about 5 ml.
The storage period needed in step 3) depend of the formulation. In general the tablet is formulated so that the contact lenses must be stored for between 10 minutes and 12 hours, preferably between 15 minutes and 4 hours, especially between 20 minutes and 2 hours.
Materials and Methods
Subtilisin A (available from Novo Nordisk as Cleanlens®Pro) ,
Proteolytic Activity
The proteolytic activity may be determined with denatured hemoglobin as substrate. In the Anson-Hemoglobin method for the determination of proteolytic activity denatured hemoglobin is digested, and the undigested hemoglobin is precipitated with trichloroacetic acid (TCA) . The amount of TCA soluble product is determined with phenol reagent, which gives a blue color with tyrosine and tryptophan.
One Anson Unit (AU) is defined as the amount of enzyme which under standard conditions (i.e. 25°C, pH 7.5 and 10 min. reaction time) digests hemoglobin at an initial rate such that there is liberated per minute an amount of TCA soluble product which gives the same color with phenol reagent as one milliequivalent of tyrosine.
A folder AF 4/5 describing the analytical method in more detail is available upon request to Novo Nordisk A/S, Denmark, which folder is hereby included by reference.
EXAMPLES
Example 1
Stability of Subtilisin A with/without 3 wt.% hvdrogen peroxide
The pH-stability of Subtilisin A (available from Novo Nordisk as Cleanlens®Pro) , was determined by letting an enzyme solution (0.0003 AU/ml) stand for between 0 to 240 minutes, at 25°C and different pH-values (from pH 2 to 7) and measure proteolytic activity before and after standing.
The result of the test shown as relative enzymatic activity is displayed in Table 1 and Table 2 below.
For each pH, the zero-time activities have been set to 100%.
Table 1 pH stability of Subtilisin A without the presence of H202
n.d.: not determined
Table 2 H2O2
As can be seen from Table 1 Subtilisin A is stable at pH 7 in the absence of H2O2. Table 2 shows that Subtilisin A is very unstable at pHs from below 7.
Claims (44)
1. A one-step method for disinfecting and cleaning contact lenses comprising the steps of a) disinfection of the contact lenses in an aqueous disinfect¬ ing solution comprising from 1 wt.% to 5 wt.% hydrogen peroxide at a pH not acceptable to the eyes, b) cleaning the contact lenses by subjecting the contact lenses to a protease being inactivated within a period of time by a pH level not acceptable to the eyes, c) neutralization of the hydrogen peroxide in the aqueous disinfecting solution with a microbial catalase being substan¬ tially active at pH 3.0 to 7.0, d) adjusting the pH in the aqueous disinfecting solution to a pH level acceptable to the eyes.
2. The one-step method according to claim 1, following the step sequence a)-b)-c)-d).
3. The one-step method according to claim 1, following the step sequence a)-c)-b)-d).
4. The one-step method according to claims 2 or 3, wherein the step b) and step c) are performed simultaneously.
5. The one-step method according to claim 1, following the step sequence a)-b)-d)-c) .
6. The one-step method according to claim 1, wherein the aqueous disinfecting solution comprises about 3 wt.% hydrogen peroxide at about pH 3.0 to 4.5, in particular about pH 3.5.
7. The one-step method according to any of claims 1 to 6, wherein the contact lenses are cleaned with a protease selected from the group of acidic aspartic proteases, cysteine prote¬ ases, serine proteases or metallo proteases.
8. The one-step method according to the claim 7, wherein the protease is an aspartic protease, such as pepsin A, B or C, or cathepsin D.
9. The one-step method according to the claim 7, wherein the protease is a cysteine protease, such as papain.
10. The one-step method according to the claim 7, wherein the protease is a metallo protease, such as Neutrase®.
11. The one-step method according to the claim 6, wherein the protease is a serine protease, preferably of the subtilisin type, including alkalophilic subtilisins, in particular subtil- isin A.
12. The one-step method according to any of claims 1 to 11, wherein the protease is inactivated at a pH level between 1.0 to 4.5, in particular 3.5.
13. The one-step method according to any of claims 1 to 12, wherein the microbial catalase is derivable from a bacteria, a filamentous fungus or a yeast.
14. The one-step method according to claim 13, wherein the microbial catalase is derivable from Aspergillus sp. , in particular Aspergillus niger.
15. The one-step method according to claim 14, wherein the catalase is CatA or CatR.
16. A tablet or capsule for disinfecting and cleaning contact lenses, wherein the tablet is a multi layer tablet, comprising i) a protease being irreversibly inactivated within a period of time in an aqueous disinfecting solution at a pH level not ac¬ ceptable to the eyes, and ii) a microbial catalase being substantially active at pH 3.0 to 7.0, iii) an agent capable of adjusting the disinfecting solution to a pH acceptable to the eyes.
17. The tablet according to claim 16, wherein the multi layer tablet, comprises a) an outer layer or coating comprising said microbial cata¬ lase, and b) a layer within said outer layer comprising said protease, and c) a core comprising said pH adjusting agent.
18. The tablet according to claim 16, wherein the multi layer tablet, comprises a) an outer layer or coating comprising said protease, b) a layer within said outer layer comprising said microbial catalase, and c) a core comprising said pH adjusting agent.
19. The tablet according to claim 16, wherein the multi layer tablet, comprises a) an outer layer or coating comprises said protease and said microbial catalase, and b) a core comprising said pH adjusting agent.
20. The tablet according to any of claims 16 to 19, wherein the protease is a protease according to any of claims 7 to 11.
21. The tablet according to any of claims 17 to 21, wherein the catalase is a microbial catalase according to any of claims 13 to 15.
22. The tablet according to any of claims 16 to 21, wherein the pH adjusting agent is a buffer or either an acid or a base.
23. The tablet according to any of claims 16 to 22, wherein at least one of said tablet or capsule layers are separated by a barrier or a membrane.
24. The tablet according to claim 23, wherein said barrier is a water soluble polymer layer, preferably a water soluble film.
25. The tablet according to claims 24, wherein said soluble polymer layer comprises compounds selected from the group of polymers of dimethylaminomethacrylate, soluble cellulose ethers, such as methylcellulose, methylhydroxycellulose, methylhydroxyethylcellulose, hydroxypropylcellulose, hy¬ droxyethylcellulose, sodium carboxymethyl cellulose, cellulose acetate phthalate, hydroxypropyimethylcellulose phthalate, a polymer of methacrylic acid and methacrylate esters, a copoly¬ mer of methacrylic acid and methacrylate esters, a copolymer of methyl vinyl ether and maleic acid anhydride, and polyvinyl alcohols.
26. The tablet according to any of claims 16 to 25, comprising a plasticizer, such as polyhydric alcohols, preferable 1,2- propylene glycol, polyethylene glycols and citrate esters.
27. The tablet according to any claims 16 to 26, having spar- ingly soluble core.
28. The tablet according to any of claims 16 to 27, being a controlled release tablet or capsule.
29. The tablet according to any of the claims 16 to 28, being of the controlled release type, wherein
- the content of the outer layer is released first, and
- said content of the second layer is released secondly after a period of time, and - the core content is released last after a period of time.
30. The tablet according to claim 29, wherein said pH adjusting agent is released slowly.
31. The tablet according to any of claims 16 to 30, wherein the content in the second layer and/or the core content is released delayed.
32. A one-step disinfecting and cleaning system for contact lenses of the type using hydrogen peroxide in an aqueous disinfecting solution for disinfecting the contact lenses, a protease for removing soil and/or debris from the contact lenses surface, and a catalase for neutralizing the hydrogen peroxide solution, comprising a) an aqueous disinfecting solution comprising 1 wt.% ti 5 wt.% hydrogen peroxide, and b) a tablet or capsule comprising i) a protease being irreversibly inactive within a period of time in an aqueous disinfecting solution at a pH level not acceptable to the eyes, and ii) a microbial catalase being substantially active at pH 3.0 to 7.0, iii) an agent capable of adjusting the aqueous disinfecting solution to a pH acceptable to the eyes.
33. The one-step system according to claim 32, wherein the hydrogen peroxide in the aqueous disinfecting solution is present in between 1 wt% to 5 wt.%, especially about 3 wt.%, at a pH in the range between 3.0 to 4.5, in particular about pH 3.5.
34. The one-step system according to claims 32 and 33, wherein the tablet or capsule is a tablet or capsule according to any of claims 16 to 31.
35. The one-step system according to any of claims 32 to 34, wherein the protease is a protease according to any of claims 7 to ll.
36. The one-step system according to any of claims 32 to 35, wherein the microbial catalase is a catalase according to any of claims 13 to 15.
37. The one-step system according to any of claims 32 to 36, wherein the pH adjusting agent is a buffer, or either an acid or a base.
38. The one-step system according to claim 37, wherein the pH adjusting agent is a buffer capable of adjusting the pH in the aqueous disinfecting solution to a pH where the enzyme is irreversibly inactivated.
39. The one-step system according to claim 38, wherein the buffer adjusts the pH in the aqueous disinfecting solution to a pH acceptable to the eyes.
40. The one-step system according to claims 38 and 39, wherein the buffer is selected from the group comprising alkali metal salts, such as potassium or sodium carbonates, acetates, bora- tes, potassium and sodium phosphates, citrates, and hydroxides, and weak acids such as acetic and boric acids.
41. A one-step procedure for disinfecting and cleaning contact lenses, comprising the steps of
1) soaking the contact lenses in a fixed amount of an aqueouε disinfecting solution comprising 1% to 5% hydrogen peroxide, and 2) adding a tablet according to any of claims 16 to 31, and
3) storing the contact lenses in the disinfecting solution for a period of time.
42. The one-step procedure according to claim 41, wherein the aqueous disinfecting solution comprises about 3% hydrogen peroxide at a pH in the range 3.0 to 4.5, in particular about pH 3.5.
43. The one-step procedure according to claims 41 and 42, wherein the fixed amount of aqueous disinfecting solution comprising hydrogen peroxide is from 1 ml to 10 ml, especially about 5 ml.
44. The one-step procedure according to any of claims 41 to 35, wherein the contact lenses is stored in the aqueous disinfect¬ ing solution for between 5 minutes and 12 hours, preferably be- tween 10 minutes and 2 hours, especially between 20 minutes and 1 hour.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK107095 | 1995-09-25 | ||
| DK1070/95 | 1995-09-25 | ||
| DK1168/95 | 1995-10-16 | ||
| DK116895 | 1995-10-16 | ||
| PCT/DK1996/000404 WO1997011722A1 (en) | 1995-09-25 | 1996-09-24 | Disinfection and cleaning of contact lenses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7083696A AU7083696A (en) | 1997-04-17 |
| AU698356B2 true AU698356B2 (en) | 1998-10-29 |
Family
ID=26065170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU70836/96A Ceased AU698356B2 (en) | 1995-09-25 | 1996-09-24 | Disinfection and cleaning of contact lenses |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0999857A1 (en) |
| JP (1) | JPH11512834A (en) |
| CN (1) | CN1197397A (en) |
| AU (1) | AU698356B2 (en) |
| CA (1) | CA2231845A1 (en) |
| WO (1) | WO1997011722A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI970012L (en) * | 1997-01-03 | 1998-07-04 | Rinne Ari E | Use of cysteine proteinases and their inhibitors in oral hygiene products |
| PT968003E (en) * | 1997-02-28 | 2002-10-31 | Albert Sturm | SOLID HYDRO-SOLUBLE MAINTENANCE PRODUCT FOR CONTACT LENSES |
| JP4499830B1 (en) * | 2009-06-29 | 2010-07-07 | 株式会社メニコン | Contact lens disinfection system |
| CN101664043B (en) * | 2009-09-30 | 2012-05-30 | 孙泽 | Disinfecting liquid used for disinfecting and cleaning water channel of hemodialysis machine and preparation method thereof |
| WO2015048223A2 (en) * | 2013-09-27 | 2015-04-02 | Novartis Ag | Compositions and methods for disinfecting and cleaning contact lenses |
| KR20160119881A (en) * | 2014-11-28 | 2016-10-17 | 주식회사 씨케이바이오텍 | Coating composition for disinfectant tablet, and preparation method of coated disinfectant tablet using the same |
| CN115350306A (en) * | 2022-10-20 | 2022-11-18 | 北京安吉贝玛健康科技有限公司 | Variable buoyancy generating type oxygen mask disinfection device |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0367723A2 (en) * | 1988-11-04 | 1990-05-09 | Ciba-Geigy Ag | Method for producing a sterile preservative-free aerosol solution |
| WO1993017721A1 (en) * | 1992-03-04 | 1993-09-16 | Genencor International, Inc. | Use of aspergillus niger catalase-r for hydrogen peroxide neutralization |
| WO1995016017A1 (en) * | 1993-12-06 | 1995-06-15 | Allergan | Sugar-based cleansing composition for contact lenses |
-
1996
- 1996-09-24 AU AU70836/96A patent/AU698356B2/en not_active Ceased
- 1996-09-24 EP EP96931760A patent/EP0999857A1/en not_active Withdrawn
- 1996-09-24 JP JP9513090A patent/JPH11512834A/en not_active Ceased
- 1996-09-24 CA CA002231845A patent/CA2231845A1/en not_active Abandoned
- 1996-09-24 WO PCT/DK1996/000404 patent/WO1997011722A1/en not_active Ceased
- 1996-09-24 CN CN 96197197 patent/CN1197397A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0367723A2 (en) * | 1988-11-04 | 1990-05-09 | Ciba-Geigy Ag | Method for producing a sterile preservative-free aerosol solution |
| WO1993017721A1 (en) * | 1992-03-04 | 1993-09-16 | Genencor International, Inc. | Use of aspergillus niger catalase-r for hydrogen peroxide neutralization |
| WO1995016017A1 (en) * | 1993-12-06 | 1995-06-15 | Allergan | Sugar-based cleansing composition for contact lenses |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2231845A1 (en) | 1997-04-03 |
| JPH11512834A (en) | 1999-11-02 |
| EP0999857A1 (en) | 2000-05-17 |
| AU7083696A (en) | 1997-04-17 |
| WO1997011722A1 (en) | 1997-04-03 |
| CN1197397A (en) | 1998-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3594308B2 (en) | Enzyme compositions and methods for contact lens cleaning | |
| US5985629A (en) | Cleaning and disinfecting contact lenses with a protease and chloramine-T or chloramine-B | |
| JP3381171B2 (en) | Hydrogen peroxide decomposing composition, and its production and use | |
| AU686599B2 (en) | Compositions and methods for destroying hydrogen peroxide | |
| AU698356B2 (en) | Disinfection and cleaning of contact lenses | |
| JPH03161091A (en) | Hydrogen peroxide decomposing composition and its application | |
| US5919698A (en) | Disinfection and cleaner of contact lenses | |
| JP3502640B2 (en) | Hydrogen peroxide decomposition composition and method of using the same | |
| JP3381172B2 (en) | Contact lens disinfecting compositions and methods | |
| JPH05503453A (en) | Hydrogen peroxide decomposition composition and method for producing and using the same | |
| JPH05504496A (en) | Hydrogen peroxide decomposition composition and method of using the same | |
| WO1997029788A1 (en) | Compositions and methods for enzyme deactivation | |
| US5783532A (en) | Enzyme compositions and methods for contact lens cleaning | |
| GB2323180A (en) | Hydrogen peroxide contact lens solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |